SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1788)10/4/2000 2:14:47 PM
From: BulbaMan  Respond to of 52153
 
Peter: Agree it's the excess overhang of biotech stock (from recently unlocked IPOs and secondaries) that's the problem. That's why I'm a strong believer in Rick's trickle-down approach and have moved quite a bit of my biotech money there. Hope we're both right in our prediction.
Speaking of biotech suppliers, you may remember SMDX, the under-$10 million market cap stock I mentioned to you. Anyway, you might want to check out today's SMDX press release.



To: Biomaven who wrote (1788)10/4/2000 9:29:21 PM
From: johnsto1  Read Replies (1) | Respond to of 52153
 
With all this extra money in the hands of the biotechs, Rick's trickle-down strategy is starting to look better and better. They can't spend it all on fancy furnishing for their offices (I hope <g>).

That's a great line...so in a trickle down situation what are the top 3...

j1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News